

A Real-world Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor

Roberto Caporali^{1,2}, Aditi Kadakia³, Oliver Howell⁴, Jayesh Patel³, Jack Milligan⁴, Sander Strengholt³, Sophie Barlow⁴, Peter C. Taylor⁵

¹Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;

²Department of Rheumatology and Medical Sciences, ASST Pini-CTO, Milan, Italy; ³AbbVie Inc., North Chicago, Illinois, United States; ⁴Adelphi Real World, Bollington, UK; ⁵Botnar Research Centre, Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK

Corresponding author and address: Aditi Kadakia, AbbVie Inc., 1 N. Waukegan Road, North Chicago, Illinois 60064; aditi.kadakia@abbvie.com

Supplemental Table S1. Outcomes in RA stratified by physician-reported disease activity at follow-up

	Level of physician-reported disease activity at follow-up				
	Total patients	Remission (DAS28 < 2.6)	LDA (DAS28 2.6–< 3.2)	MDA (DAS28 ≥ 3.3–5.1)	HDA (DAS28 > 5.1) currently
Physician-reported assessment of severity of RA at follow-up					
Total	n=503	n=244	n=172	n=82	n=5
Mild	369 (73%)	235 (96%)	133 (77%)	1 (1%)	0 (0%)
Moderate	122 (24%)	7 (3%)	36 (21%)	78 (95%)	1 (20%)
Severe	12 (2%)	2 (1%)	3 (2%)	3 (4%)	4 (80%)
Physician-reported level of pain at follow-up					
Total	n=503	n=244	n=172	n=82	n=5
None	170 (34%)	155 (64%)	14 (8%)	1 (1%)	0 (0%)
Mild	241 (48%)	87 (36%)	135 (78%)	19 (23%)	0 (0%)
Moderate	83 (17%)	2 (1%)	22 (13%)	58 (71%)	1 (20%)
Severe	9 (2%)	0 (0%)	1 (1%)	4 (5%)	4 (80%)
Physician-reported symptoms experienced at follow-up					
Total	n=503	n=244	n=172	n=82	n=5

Tender joints	256 (51%)	73 (30%)	112 (65%)	66 (80%)	5 (100%)
Stiffness in joints	200 (40%)	61 (25%)	84 (49%)	52 (63%)	3 (60%)
Fatigue	156 (31%)	45 (18%)	61 (35%)	48 (59%)	2 (40%)
Swollen joints	122 (24%)	14 (6%)	53 (31%)	50 (61%)	5 (100%)
Pain on movement	117 (23%)	29 (12%)	46 (27%)	41 (50%)	1 (20%)
Loss of movement/loss of mobility	60 (12%)	14 (6%)	21 (12%)	24 (29%)	1 (20%)
Pain at rest	63 (13%)	10 (4%)	21 (12%)	31 (38%)	1 (20%)
Cracking joints	64 (13%)	29 (12%)	24 (14%)	11 (13%)	0 (0%)
Loss of grip	58 (12%)	15 (6%)	21 (12%)	21 (26%)	1 (20%)
Sleep disturbance	52 (10%)	10 (4%)	17 (10%)	22 (27%)	3 (60%)
Psychological disorders (depression/anxiety)	47 (9%)	12 (5%)	20 (12%)	13 (16%)	2 (40%)
Persistent lower back pain	31 (6%)	7 (3%)	12 (7%)	12 (15%)	0 (0%)
None (the patient is currently asymptomatic)	106 (21%)	99 (41%)	6 (3%)	1 (1%)	0 (0%)

DAS28, Disease Activity Score-28; HDA, high disease activity; LDA, low disease activity; MDA, moderate disease activity; RA, rheumatoid arthritis.

Supplemental Table S2. Spearman’s correlation of physician reported DAS28 and objective DAS28 scores collected at that consultation or from medical records in the 4 weeks prior

Spearman’s Rho = 0.6722	N=146	p-value <0.0001
-------------------------	-------	-----------------

DAS28, Disease Activity Score-28.